1-3 of 3
Amulya Uppala
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study

Tae Min Kim, Seok-Goo Cho, Michal Taszner, Geoffrey Chong, Jingxian Cai, Amulya Uppala, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, John N. Allan
Journal: Blood
Blood (2024) 144 (Supplement 1): 862.
https://doi.org/10.1182/blood-2024-200190
Published: 2024
Journal Articles

Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 Study

Seok-Goo Cho, Tae Min Kim, Michal Taszner, Tsai-Yun Chen, Aafia Choudhry, Melanie Ufkin, Amulya Uppala, Ayesha Sabir, Hesham Mohamed, Srikanth Ambati, Emmanuel Bachy
Journal: Blood
Blood (2024) 144 (Supplement 1): 6302.
https://doi.org/10.1182/blood-2024-200770
Published: 2024
Journal Articles

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Jose. C. Villasboas, Tae Min Kim, Michal Taszner, Silvana Novelli, Seok-Goo Cho, Michele Merli, Ana Jimenez Ubieto, Benoit Tessoulin, Michelle Poon, Jan Walewski, Shuhua Yi, Yuqin Song, Geoffrey Chong, Stefano Luminari, Emmanuel Bachy, Stephanie Guidez, Aranzazu Alonso, Deepa Jagadeesh, Wei Zhang, Laura Magnano, Elżbieta Iskierka-Jażdżewska, Monica Tani, Jessica Cai, Amulya Uppala, Saleem Shariff, Lei Chi, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, David Tucker
Journal: Blood
Blood (2023) 142 (Supplement 1): 3041.
https://doi.org/10.1182/blood-2023-181650
Published: 2023